View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recaps for Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers focuses on areas of clinical challenge encountered by practicing oncologists, along with emerging immunotherapeutic approaches being developed to tackle these challenges.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers

Release Date: April 28, 2017
Expiration Date: April 28, 2018
Media: Internet - based


Activity Overview

This activity focuses on standards of care and emerging strategies in immunotherapy for cancers of the lung, head and neck, and bladder. It features a series of short video interviews with leading experts in the field. The content and interviews are based on presentations given in February 2017 at Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers, a live symposium held adjunct to a major immuno-oncology conference that took place in Orlando, Florida. In their interviews, program chair Roy Herbst, MD, PhD; Ezra Cohen, MD; Robert Ferris, MD, PhD; and Daniel Petrylak, MD, offer guidance and perspective on standards of care, the clinical implication of new data, and novel investigational agents and approaches. This program is geared to meet the needs of busy researchers and clinicians who strive to advance the management of patients with these tumors.

CME Activity Table of Contents

  • Case 1: Frontline Therapy for Squamous Non–Small Cell Lung Cancer
    Roy Herbst, MD, PhD
  • Case 2: p16-Positive, HPV-Positive Head and Neck Squamous Cell Carcinoma
    Robert Ferris, MD, PhD
  • Case 3: Metastatic Cisplatin-Refractory Urothelial Carcinoma
    Daniel Petrylak, MD
  • Case 4: Pneumonitis in a Patient Receiving Anti–PD-1 Therapy for Non–Small Cell Lung Cancer
    Ezra Cohen, MD

Requirements for Successful Completion

  • You will need to login to participate in the activity.
  • Each presentation may contain interactive questions. You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation, and then click on “request for credit”. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals are invited to participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  • Explain clinically unmet needs in the management of non–small cell lung cancer, head and neck squamous cell carcinoma (HNSCC), and bladder cancer
  • Describe how the immune system can be harnessed to treat cancer and the mechanistic rationale for the application of checkpoint inhibition strategies to target specific solid tumors
  • Interpret recent findings from clinical trials conducted with immuno-oncology strategies for the treatment of lung cancer, HNSCC, and bladder cancer
  • Describe the current status of biomarkers as a method to personalize care with the use of immuno-oncology strategies
  • Evaluate methods to mitigate treatment-related toxicities via proactive mitigation and management of immune-related adverse events (irAEs)

Faculty, Staff, and Planners' Disclosures


Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosure: AstraZeneca, Eli Lilly, Genentech/Roche, Merck, Pfizer; Grant/Research Support: Genentech, Merck

Ezra Cohen, MD
Associate Director, Moores Cancer Center
Professor of Medicine
UC San Diego Health - La Jolla
La Jolla, CA

Disclosure: Consultant: Eisai; Pfizer; Merck; AstraZeneca; Bristol-Myers Squibb; Human Longevity;

Robert L. Ferris, MD, PhD, FACS
Professor, Vice-Chair for Clinical Operations
Chief, Division of Head and Neck Surgery Departments of Otolaryngology, Radiation
Oncology, and Immunology
Co-Leader, Cancer Immunology Program
University of Pittsburgh Cancer Institute
Pittsburg, PA

Disclosure: Grant/Research Support: AstraZeneca/MedImmune, Bristol-Myers Squibb, VentiRx Pharmaceuticals; Advisory Board: AstraZeneca/MedImmune, Bristol-Myers Squibb, Lilly, Merck, Pfizer; Clinical Trial: AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck

Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology)
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
New Haven, CT

Disclosure: Grant/Research Support: OncoGenex, Progenics, Johnson & Johnson, Merck, Millennium, Medivation, Pfizer, Roche Laboratories, Tyme Pharmaceuticals; Consultant: Bayer, Bellicum, Dendreon, Sanofi-Aventis, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche Laboratories, Tyme Pharmaceuticals; Stock/Shareholder: Bellicum, Tyme.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By